Biogen Expects Confirmatory Aduhelm Data In 2026, But Is It Too Late?
Data on rivals will be available well before
Biogen's update on the timeline for running a confirmatory study of the Alzheimer's treatment is faster than the nine years required by FDA under the accelerated approval.
